Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
PMV Pharmaceuticals, Inc. (PMVP) had Consolidated Net Income/Loss of $-21.21M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-21.21M |
|
-- |
|
-- |
|
$22.88M |
|
$-22.88M |
|
$1.67M |
|
$-21.20M |
|
$-21.20M |
|
$-21.21M |
|
$-21.21M |
|
|
Consolidated Net Income/Loss |
$-21.21M |
$-21.21M |
|
$-22.88M |
|
$-23.57M |
|
52.01M |
|
52.01M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$145.31M |
|
$0.29M |
|
$7.54M |
|
$152.85M |
|
$11.61M |
|
-- |
|
$0.64M |
|
$12.25M |
|
$140.60M |
|
$140.60M |
|
$140.60M |
|
52.99M |
|
| Cash Flow Statement Financials | |
$-36.57M |
|
$39.70M |
|
$0.11M |
|
$40.88M |
|
$44.13M |
|
$3.25M |
|
$3.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-36.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.08% |
|
-15.08% |
|
-13.88% |
|
-15.08% |
|
$2.65 |
|
$-0.70 |
|
$-0.70 |
|